Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

The reduction of our net loss in 2025 from 2024 was primarily related to the LifeSci Capital LLC judgment expense and reimbursement of legal costs, clinical trial related settlement expenses with A-IR ...

At the heart of these award‑winning solutions is Aptar Beauty’s patented Gaïa reloadable airless technology, with a custom ...

North American lithium producer Elevra Lithium Limited ('Elevra or Company”) (ASX:ELV; NASDAQ:ELVR) announced today the outcomes of an Updated Scoping Study for expansion of the existing North ...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the ...

Read more about Healthcare AI rules lag behind ethics as hospitals race toward automated medicine on Devdiscourse ...

Lithium Argentina AG ("Lithium Argentina" or the "Company") (TSX: LAR) (NYSE: LAR) today announced its first quarter 2026 results. Unless otherwise ...

ReMEDy1 Data Informing Current Stroke Trial -- In moderate stroke patients (NIHSS 5-15), a 19% absolute functional outcome ...

Sir David Attenborough has mastered the craft of storytelling. He has undoubtedly inspired generations of people around the ...

During 2025, Phio strengthened its balance sheet through a series of equity financings and warrant exercises that generated approximately $23.7 million in net proceeds. These transactions extended the ...

In the summer of 2024, during the WNBA’s Olympic break, several Atlanta Dream players who weren’t competing in Paris had ...